Comparative Effectiveness of Riamilovir and Umifenovir for Treating Influenza

Abstract

The present study focuses on the comparative assessment of the therapeutic efficacy of the antiviral drugs riamilovir and umifenovir in the treatment of patients diagnosed with influenza. The aim of the study was to compare the clinical efficacy and safety, as well as the incidence of complications, of the use of antiviral drugs riamilovir and umifenovir and the use of only symptomatic therapy in patients with a confirmed diagnosis of influenza. All patients were hospitalized at the Regional Clinical Hospital No. 2 in Vladivostok. The study included 150 patients, who were divided into 3 groups (50 patients in each group), comparable in gender, age, and admission to the hospital. Patients of the first group received riamilovir, the second group received uminofenovir, patients of the third group received only symptomatic therapy (control group). The duration of clinical manifestations of the disease, hematological disorders, as well as the content of cytokines TNF-α and IL-10 in blood serum were assessed. The incidence of complications in each group was taken into account. As a result of the study, it was found that the inclusion of the antiviral drugs riamilovir and umifenovir in the therapy of influenza decreases the amount of the pro-inflammatory cytokine TNF-α after 5 days of treatment; and in case of symptomatic therapy its level significantly exceeded the reference values. The level of anti-inflammatory cytokine IL-10 on the 5th day of treatment in the main group was three times lower than in the control group. Thus, riamilovir and umifenovir effectively relieve the main symptoms of the disease, reduce the incidence of complications, and reduce the severity of the inflammatory response by the 5th day of treatment.

From HIV to COVID-19, Molecular mechanisms of pathogens’ trade-off and persistence in the community, potential targets for new drug development

“…Blocking HIV entry into macrophages by aromatase inhibitors has been recently FDA-approved. Inhibitors of viral proteases mediating lung entry of SARS-CoV-2 and influenza attachment to sialic acid are also new potential targets for drug development (Aspatwar et al 2018 ; Balestra et al 2020 ; Hoogeveen and Boonstra 2020 ; Pasquereau and Herbein 2022 ; Popov et al 2021 ; Shapira 2022 ; Zheng and Abramovitch 2020 ).…”